Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply ...

The contract enables USRC attending physicians to prescribe Vafseo® for patients on dialysis as deemed clinically appropriate when it is expected to be ...

Akebia Therapeutics, US Renal Care enter deal to offer Vafseo to ...

Akebia Therapeutics and U.S. Renal Care sign commercial supply contract to enable access to Vafseo (vadadustat) for patients on dialysis.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney ...

Akebia Therapeutics and U.S. Renal Care sign commercial supply ...

“[USRC] is pleased to partner with Akebia to make Vafseo accessible to our patients,” said Mark Caputo, chief executive officer (CEO), USRC.

Akebia, US Renal Care sign dialysis treatment supply deal

A biopharmaceutical company and US Renal Care, a dialysis service provider, today announced a multi-year commercial supply contract for Vafseo.

Akebia Therapeutics Signs Commercial Supply Contract with ...

In March 2024, the U.S. Food and Drug Administration approved Vafseo for the treatment of anemia due to chronic kidney disease in adults who ...

Akebia Therapeutics Signs Commercial Supply Contract with ...

In March 2024 , the U.S. Food and Drug Administration approved Vafseo for the treatment of anemia due to chronic kidney disease in adults who ...

Press Releases - Akebia Therapeutics

October 7, 2024. Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis.

Akebia signs commercial supply contract with dialysis organization

Akebia (AKBA) Therapeutics announced that it has signed a multi-year commercial contract with one of the nation's leading providers of kidney care services.

Akebia Therapeutics Signs Commercial Supply Contract with ...

The contract is with a comprehensive kidney care provider serving over 200,000 patients at thousands of U.S. dialysis centers. Vafseo ...

Akebia Therapeutics Signs Commercial Supply Contract with a ...

In March 2024, the U.S. Food and Drug Administration approved Vafseo for the treatment of anemia due to chronic kidney disease in adults who ...

Akebia Therapeutics Reports Third Quarter 2024 Financial Results ...

We also recently partnered with U.S. Renal Care (USRC) to ... Akebia has entered into commercial supply contracts for Vafseo with dialysis ...

Form 8-K for Akebia Therapeutics INC filed 10/22/2024

Akebia Therapeu cs Signs Commercial Supply ... kidney care provider serving more than 200,000 pafients at its thousands of U.S. dialysis centers.

Akebia Therapeutics secures dialysis drug contract - Investing.com

Akebia has signed a substantial commercial supply agreement with U.S. Renal Care for Vafseo, set to be available in January 2025. Additionally, ...

Akebia Therapeutics on X: "PRESS RELEASE: Akebia Therapeutics ...

PRESS RELEASE: Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract. Link here: https://t.co/l0mLQTzuIg.

Akebia Therapeutics and US Renal Care initiate VOICE trial of ...

Akebia Therapeutics and US Renal Care ... Renal Care sign commercial supply contract to enable access to Vafseo for patients on dialysis ...

Akebia Therapeutics Inc. (AKBA:US) | News & Upcoming Events

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis. PR Newswire OCT 7 ...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq ...

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis. September 05, 2024.

Renal Exchange on X: "Akebia Therapeutics and U.S. Renal Care ...

... dialysis patients starting January 2025. Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo®...

Akebia Therapeutics to Report Third Quarter 2024 Financial Results ...

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis. September 05, 2024.